News Releases

Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President and Representative Director: Masayuki Kobayashi) announced today that it has applied for the additional indications of complicated skin and soft tissue infections (including diabetic foot infections) for its β-lactamase inhibitor combination product ZOSYN 2.25 and ZOSYN 4.5, and ZOSYN 4.5 for I.V. infusion bag (generic name: tazobactam and piperacillin) to the Japanese Ministry of Health, Labour and Welfare.

ZOSYN is an injectable antibacterial combination product consisting of the β-lactamase inhibitor tazobactam that Taiho discovered and the semisynthetic antibiotic piperacillin that Toyama Chemical Co., Ltd. (HQ: Tokyo, President and Representative Director: Junji Okada) discovered, in a ratio of 1:8 in potency for intravenous administration.

Taiho holds the marketing authorization for ZOSYN in Japan, and Taisho Toyama Pharmaceutical Co., Ltd. (HQ: Tokyo, President and Representative Director: Kenichi Fujita) is marketing the product. In July 2008, ZOSYN was approved in Japan for the treatment of septicemia, pneumonia, pyelonephritis, and complicated cystitis in adults and children. In September 2012, it received approval for the indications of peritonitis, intra-abdominal abscess, cholecystitis, and cholangitis. And in June 2015, it received approval for the indication of febrile neutropenia. ZOSYN is recommended as a first choice in the guidelines issued by the medical societies in the countries including the US and Europe for treatment of various infectious diseases, and is well recognized as a standard therapeutic agent for bacterial infections around the world.

Taiho remains committed to making further contributions to patients and medical practitioners engaged in the treatment of infectious diseases.

About complicated skin and soft tissue infections

Complicated skin and soft tissue infections are general term for purulent inflammations characterized by diffusion from the dermis to subcutaneous tissue. They are categorized by having a lesion site as well as a superficial or profound effect according to extent and depth. Erosive, ulcerated secondary infections include bedsores, leg ulcers, radiation ulcers, and diabetic gangrene that extend to the deep skin layers. Moderate and severe conditions often require treatment with injectable antibiotics.